Immuneering receives fast track designation for IMM-1-104 from FDA

Immuneering announced that the FDA granted fast track designation for its clinical-stage program, IMM-1-104, as a first-line treatment for patients with pancreatic ductal adenocarcinoma, or PDAC. In February, the company announced Fast Track designation for IMM-1-104 as second-line treatment for patients with PDAC who have failed one previous line of therapy. IMM-1-104 is designed to provide universal-RAS activity through Deep Cyclic Inhibition of the MAPK pathway with once-daily oral dosing.